a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") association a(MESH:"Cardiovascular System")

PubMed:24511233

Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia.

Related Edges 3

• a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") association a(MESH:"Gastrointestinal Tract")
• a(MESH:"Cardiovascular System") association a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")
• a(MESH:"Gastrointestinal Tract") association a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.